|Day Low/High||34.57 / 36.80|
|52 Wk Low/High||6.28 / 40.98|
Data Demonstrate Clinical Effectiveness and Superior Immunogenicity Profile of AAV5 Gene Therapy in Severe and Moderate-Severe Hemophilia B Patients
Here are how some of the conference presenters are performing on the market Wednesday
~ New Nonclinical Data on AMT-061 to be Presented Saturday, December 9, 2017 ~
~ First Investigational Gene Therapy in Huntington's Disease to Receive Designation ~
Live webcast of gene therapy panel discussion on Thursday, September 7 at 11:00 am EDT
~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.